Tropical spastic paraparesis and HTLV-I associated myelopathy in infancy. A case report and review of the literature;Paraparesia espástica tropical/mielopatía asociada al HTLV-I en la infancia. Caso clínico y revisión bibliográfica

Revista de Neurologia

Volumn 39, Issue 12, 2004, Pages 1133-1136

  Quintas, Sofia ^a,b   Moreno, T ^a   Lobo Antunes, N ^a   Levy Gomes, A ^a  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b NONE   (Portugal)

Author keywords

Antiretroviral therapy; HTLV I; Infancy; Interferon alfa; Myelopathy; Spastic paraparesis

Indexed keywords

ALPHA INTERFERON; ANTIRETROVIRUS AGENT; CORTICOSTEROID;

CASE REPORT; CHILD; CHILDHOOD DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST; ENDEMIC DISEASE; EVOKED SOMATOSENSORY RESPONSE; GUINEA; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; PROGNOSIS; REVIEW; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; SPINAL CORD LESION; TROPICS; VIRUS INFECTION;

EID: 22144485884     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3912.2003611     Document Type: Review

References (43)

1. Román GC, Spencer PS, Schoenberg BS. Tropical myeloneuropathies: the hidden endemias. Neurology 1985; 35: 1158-70.
2. Cruickshank JK, Rudge P, Dalgleish AG, Newton M, McLean BN, Barnard O, et al. Tropical spastic paraparesis and human T cell lymphotropic virus type I in the United Kingdom. Brain 1989; 112: 1057-90.
3. Vernant JC, Maurs L, Gessain A, Barin F, Gout O, Delaporte JM, et al. Endemic tropical spastic paraparesis associated with human T-lymphotropic virus type I: a clinical and seroepidemiological study of 25 cases. Ann Neurol 1987; 21: 123-30.
4. Léon-S FE, De Castro-Costa CM, Gaffga M. Discrepancy, coincidence or evidence in chronic idiopathic spastic paraparesis throughout the world: a meta-analysis of 2811 patients. Arq Neuropsiquiatr 1997; 55: 530-5.
5. De Castro-Costa CM, Carton H, Goubau P, D'Almeida JAC. Brazilian studies on tropical spastic paraparesis: a meta-analysis. Arq Neuropsiquiatr 1994; 52: 585-91.
6. Gessain A, Barin F, Vernant JC, Gout O, Maurs L, Calender AG. Antibodies to human T-lymphotropic virus type I in patients with tropical spastic paraparesis. Lancet 1985; 2: 407-9.
7. Orland JR, Engstrom J, Fridey J, Sacher RA, Smith JW, Nass C, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV outcomes study. Neurology 2003; 61: 1588-94.
8. Hollsberg P, Hafler DA. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993; 328: 1173-82.
9. Osame M, Igata A, Matsumoto M, Usuku K, Kosaka K. HTLV-I associated myelopathy: a report of 85 cases [abstract]. Ann Neurol 1987; 22: 116.
10. Kayembe K, Goubau P, Desmyter J, Vlietinck R, Carton H. A cluster of HTLV-I associated tropical spastic paraparesis in Equateur (Zaire): ethnic and familial distribution. J Neurol Neurosurg Psychiatry 1990; 53: 4-10.
11. Carod-Artal FJ, del Negro MC, Vargas AP, Rizzo I. Síndrome cerebelar y neuropatía periférica como manifestación de la infección por el virus linfotrópico humano de células T, HTLV-I. Rev Neurol 1999; 29: 932-5.
12. LaGrenade L, Morgan C, Carberry C, Hanchard B, Fletcher V, Gray R, et al. Tropical spastic paraparesis occurring in HTLV-I associated infective dermatitis: report of two cases. West Indian Med J 1995; 44: 34-5.
13. Zaninovic V. Tropical spastic paraparesis. Lancet 1987; 2: 280.
14. McKhann G II, Gibbs CJ Jr, Mora CA, Rodgers-Johnson PE, Liberski PP, Gdula WJ, et al. Isolation and characterization of HTLV-I from symptomatic family members with tropical spastic paraparesis (HTLV-I encephalomyeloneuropathy). J Infect Dis 1989; 160: 371-9.
15. Araújo AP, Fontenelle LM, Pádua PA, Maia-Filho HS, Araújo AQ. Juvenile human T lymphotropic virus type 1-associated myelopathy. Clin Infect Dis 2002; 35: 201-4.
16. Maloney EM, Wiktor SZ, Palmer P, Cranston B, Pate EJ, Cohn S, et al. A cohort study of health effects of human T-cell lymphotropic virus type I infection in Jamaican children. Pediatrics 2003; 112: 136-42.
17. LaGrenade L, Sonoda S, Miller W, Pate E, Rodgers-Johnson P, Hanchard B, et al. HLA DRB1*DQB1 haplotype in HTLV-I associated familial infective dermatitis may predict development of HTLV-I myelopathy/ tropical spastic paraparesis. Am J Med Genet 1996; 61: 37-41.
18. De Castro-Costa CM, Carton H, Santos TJT. HTLV-I negative tropical spastic paraparesis. A scientific challenge. Arq Neuropsiquiatr 2001; 59: 289-94.
19. Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MPJ analysis and a two-year follow-up study after corticosteroid therapy. J Neurol Sci 1991; 106: 41-9.
20. Gazzola P, Cocito L, De Maria A, Gabutti G, Mancardi GL. Successful 2-year therapy with systemic interferon-alpha for HTLV-I-associated myelopathy. J Neurol Sci 1999; 162: 205-7.
21. Carod-Arial FJ, Melo M, Alves R, Brenner C, del Negro MC. Formas subagudas de infecion por el virus HTLV-I potencialmente tratables. Rev Neurol 2000; 31: 32-5.
22. Porta-Etessam J, Molina JA, Bermejo F. Interferon-alpha treatment in a case of HTLV-I-associated myelopathy. Eur J Neurol 1998; 5: 515.
23. Honig LS, Lipka JJ, Young KY, Weiss JH, Foung SKH. HTLV-I-associated myelopathy in a Californian: diagnosis by reactivity to a viral recombinant antigen. Neurology 1991; 41: 448-50.
24. Umehara F, Izumo S, Nakagawa M, Ronquillo AT, Takahashi K, Matsumuro K, et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 1993; 52: 424-30.
25. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1: 1031-2.
26. Osame M, Matsumoto M, Usuku K, Izumo S, Ijichi N, Amitani H, et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemia like cells. Ann Neurol 1987; 21: 117-22.
27. Duncan J, Rudge P. Methylprednisolone therapy in tropical spastic paraparesis. J Neurol Neurosurg Psychiatry 1990; 53: 173-4.
28. Sheremata WA, Benedict D, Squilacote DC, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 1993; 43: 2125-9.
29. Taylor GP, Hall SE, Navarrete S, Michie CA, Davis R, Witkover AD, et al. Effect of lamivudine on human T-cell leukemia virus type I (HTLV-I) DNA copy number, T-cell phenotype and anti-Tax cytotoxic T-cell frequency in patients with HTLV-I associated myelopathy. J Virol 1999; 73: 10289-95.
30. Izumo S, Goto I, Itoyama Y, Okajima T, Watanable S, Kuroda Y, et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 1996; 46: 1016-21.
31. Yamasaki K, Kira J, Koyanagi Y, Kawano Y, Miyano-Kurosaki N, Nakamura M, et al. Long term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 1997; 147: 135-44.
32. Cabrera-Gómez JA, López-Saura P. Actualización del tratamiento con interferón alfa en las enfermedades del sistema nervioso. Rev Neurol 1999; 29: 1225-35.
33. Misra AK, Mishra SK, Eigen AC, Tourtellotte WW. Successful immunosuppressive therapy for HTLV-I-associated myelopathy. J Neurol Sci 1994; 122: 155-6.
34. Matsuo H, Nakamura T, Tsujihata M, Kinoshita I, Satoh A, Tomita I, et al. Plasmapheresis in treatment human T-lymphotropic virus type-I associated myelopathy. Lancet 1988; 2: 1109-13.
35. Narukawa N, Shizaki K, Abe T, Kobata H, Akizawa T. Plasma exchange for the treatment of human T-cell lymphotropic virus type I associated myelopathy. Ther Apher 2001; 5: 491-3.
36. Kataoka A, Imai H, Inayoshi S, Tsuda T. Intermittent high-dose vitamin C therapy in patients with HTLV-I-associated myelopathy. J Neurol Neurosurg Psychiatry 1993; 56: 1213-6.
37. Harrington WJ Jr, Sheremata WA, Snodgrass SR, Emerson S, Phillips S, Berger JR. Tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses 1991; 7: 1031-43.
38. Nagasato K, Nakamura T, Ichinose K, Nishiura Y, Ohishi K, Shibayama K, et al. Heparin treatment in patients with human T-lymphotropic virus type I (HTLV-I)-associated myelopathy: a preliminary study. J Neurol Sci 1993; 115: 161-8.
39. Shirabe S, Nakamura T, Tsujino A, Nishiura Y, Furuya T, Goto H, et al. Successful application of pentoxifylline in the treatment of HTLV-I-associated myelopathy. J Neural Sci 1997; 151: 97-101.
40. Lehky TJ, Levin MC, Kubota R, Bamford R, Flerlage AN, Soldan SS, et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 1998; 44: 942-7.
41. Gill PS, Harrington W, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, et al. Treatment of adult T-cell leukaemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995; 332: 1744-8.
42. Shepherd FA, Beaulieu R, Gelmon K, Thuat CA, Sawka C, Read S, et al. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's Sarcoma associated with human immunodeficiency virus infection: a Canadian HIV clinical trials network study. J Clin Oncol 1998; 16: 1736-42.
43. Machuca A, Soriano V. In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. J Acquir Immune Defic Syndr 2000; 24: 189-93.